X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3897) 3897
Book Review (650) 650
Publication (513) 513
Book Chapter (31) 31
Conference Proceeding (27) 27
Dissertation (9) 9
Book / eBook (1) 1
Newspaper Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (2925) 2925
humans (2239) 2239
oncology (1542) 1542
animals (1260) 1260
mek (1073) 1073
cancer (1053) 1053
melanoma (893) 893
cell line, tumor (803) 803
cell biology (776) 776
mek inhibition (763) 763
apoptosis (754) 754
mutation (710) 710
mice (691) 691
female (649) 649
phosphorylation (646) 646
signal transduction (639) 639
biochemistry & molecular biology (615) 615
kinases (600) 600
activation (585) 585
mek inhibitors (577) 577
braf (563) 563
male (537) 537
protein kinase inhibitors - pharmacology (466) 466
proteins (452) 452
antineoplastic agents - pharmacology (441) 441
tumors (433) 433
map kinase (432) 432
expression (419) 419
melanoma - drug therapy (413) 413
erk (400) 400
article (394) 394
metastatic melanoma (391) 391
research (389) 389
pharmacology & pharmacy (388) 388
signal transduction - drug effects (380) 380
care and treatment (378) 378
raf/mek/erk pathway (373) 373
apoptosis - drug effects (366) 366
metastasis (364) 364
extracellular signal-regulated kinase (363) 363
inhibition (362) 362
mek inhibitor (361) 361
analysis (357) 357
map kinase signaling system - drug effects (351) 351
antineoplastic agents - therapeutic use (349) 349
vemurafenib (340) 340
proto-oncogene proteins b-raf - genetics (335) 335
cell proliferation - drug effects (328) 328
growth (311) 311
open-label (308) 308
pathway (307) 307
improved survival (302) 302
extracellular signal-regulated map kinases - metabolism (297) 297
resistance (293) 293
mutations (286) 286
chemotherapy (284) 284
cells (279) 279
acquired-resistance (278) 278
health aspects (278) 278
middle aged (278) 278
genetic aspects (277) 277
gene expression (276) 276
melanoma - genetics (273) 273
inhibitors (271) 271
survival (267) 267
protein kinase inhibitors - therapeutic use (265) 265
cell proliferation (264) 264
melanoma - pathology (263) 263
xenograft model antitumor assays (253) 253
cancer therapies (249) 249
proto-oncogene proteins b-raf - antagonists & inhibitors (246) 246
therapy (245) 245
aged (244) 244
enzyme inhibitors - pharmacology (240) 240
ras (238) 238
mitogen-activated protein kinases - metabolism (236) 236
mitogen-activated protein kinase kinases - antagonists & inhibitors (228) 228
neoplasms (228) 228
niacinamide - analogs & derivatives (227) 227
sorafenib (227) 227
adult (223) 223
targeted therapy (221) 221
rats (219) 219
immunotherapy (218) 218
drug therapy (213) 213
mitogen-activated protein kinase kinases - metabolism (212) 212
mapk (211) 211
map kinase signaling system (210) 210
protein kinases (210) 210
cell cycle (209) 209
molecular targeted therapy (209) 209
drug resistance (199) 199
kinase (199) 199
medicine, research & experimental (196) 196
antineoplastic agents (195) 195
dabrafenib (195) 195
patients (195) 195
trametinib (195) 195
activated protein-kinase (193) 193
research article (193) 193
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3899) 3899
German (21) 21
French (9) 9
Japanese (2) 2
Korean (2) 2
Spanish (2) 2
Chinese (1) 1
Italian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Clinical Cancer Research, ISSN 1078-0432, 12/2015, Volume 21, Issue 24, pp. 5412 - 5414
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 07/2012, Volume 367, Issue 2, pp. 107 - 114
Journal Article
International Journal of Cancer, ISSN 0020-7136, 02/2013, Volume 132, Issue 3, pp. E149 - E157
Inhibition of centromere‐associated protein‐E (CENP‐E) has demonstrated preclinical anti‐tumor activity in a number of tumor types including neuroblastoma. A... 
CENP‐E | neuroblastoma | MEK | Ras | GSK923295 | ERK | CENP-E | MAP KINASE | RECEPTOR | ONCOLOGY | PATHWAY | THERAPEUTIC-EFFICACY | ALK KINASE | MUTATIONS | MITOTIC CHECKPOINT | SIGNAL-REGULATED KINASE | Lung Neoplasms - drug therapy | Colonic Neoplasms - genetics | Apoptosis - drug effects | Colonic Neoplasms - drug therapy | Humans | Mitogen-Activated Protein Kinase 3 - antagonists & inhibitors | Drug Resistance, Neoplasm | Biomarkers, Tumor | Chromosomal Proteins, Non-Histone - antagonists & inhibitors | Pancreatic Neoplasms - drug therapy | RNA Interference | Dacarbazine - pharmacology | Dacarbazine - analogs & derivatives | Antineoplastic Agents - pharmacology | Benzamides - pharmacology | Sarcosine - analogs & derivatives | Neuroblastoma - pathology | Sarcosine - pharmacology | Camptothecin - analogs & derivatives | Lung Neoplasms - genetics | M Phase Cell Cycle Checkpoints - drug effects | Mitogen-Activated Protein Kinase 3 - genetics | Pancreatic Neoplasms - genetics | Drug Synergism | Bridged Bicyclo Compounds, Heterocyclic - pharmacology | MAP Kinase Signaling System - drug effects | Mitogen-Activated Protein Kinase 3 - metabolism | Neuroblastoma - drug therapy | Cell Line, Tumor | Cell Proliferation - drug effects | Neuroblastoma - metabolism | RNA, Small Interfering | Camptothecin - pharmacology | Drug Screening Assays, Antitumor | Prevention | Colon cancer | Lung cancer | Oncology, Experimental | Genes | Research | Drug therapy, Combination | Protein kinases | Cancer | Proteins | Chemotherapy | Kinases | Index Medicus | Apoptosis
Journal Article
The Prostate, ISSN 0270-4137, 11/2015, Volume 75, Issue 15, pp. 1747 - 1759
BACKGROUND. PTEN deletion, mutation or reduced expression occurs in 63% of metastatic prostate tumors, resulting in the activation of PI3K and its downstream... 
castration‐resistant prostate cancer | targeted therapy | prostate cancer | MEK inhibitor | PI3K inhibitor | castration-resistant prostate cancer | APOPTOSIS | ACTIVATION | MEMBRANE | COMBINATION | PATHWAY | MOUSE MODEL | GROWTH | ENDOCRINOLOGY & METABOLISM | UROLOGY & NEPHROLOGY | CARCINOMA | FEEDBACK | TOR Serine-Threonine Kinases - metabolism | Apoptosis - drug effects | Humans | Caspase 3 - metabolism | Male | Phosphatidylinositol 3-Kinases - metabolism | Phosphatidylinositol 3-Kinases - antagonists & inhibitors | Prostatic Neoplasms, Castration-Resistant - pathology | Quinolines - pharmacology | TOR Serine-Threonine Kinases - antagonists & inhibitors | Phosphorylation - drug effects | Proto-Oncogene Proteins c-akt - metabolism | Benzimidazoles - therapeutic use | Treatment Outcome | Prostatic Neoplasms, Castration-Resistant - drug therapy | Sulfonamides - pharmacology | Prostatic Neoplasms, Castration-Resistant - metabolism | Drug Synergism | Xenograft Model Antitumor Assays | Animals | Sulfonamides - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Cell Line, Tumor | Benzimidazoles - pharmacology | Mice | Protein Kinase Inhibitors - pharmacology | Quinolines - therapeutic use | Cell Cycle - drug effects | Immunohistochemistry | Care and treatment | Analysis | Prostate cancer | Sugars | Cancer | Monosaccharides | Index Medicus
Journal Article
Cancer Discovery, ISSN 2159-8274, 01/2014, Volume 4, Issue 1, pp. 61 - 68
Journal Article
Cancer Discovery, ISSN 2159-8274, 03/2012, Volume 2, Issue 3, pp. 227 - 235
BRAF mutations occur in 10% to 15% of colorectal cancers and confer adverse outcome in the metastatic setting. Although RAF inhibitors such as vemurafenib... 
CELLS | CETUXIMAB | MELANOMA | ONCOLOGY | KINASE | MUTATION | RESISTANCE | WILD-TYPE BRAF | KRAS | ANTITUMOR-ACTIVITY | MEK INHIBITORS
Journal Article
eLife, ISSN 2050-084X, 01/2017, Volume 6
Journal Article
Journal Article
NATURE, ISSN 0028-0836, 12/2010, Volume 468, Issue 7326, pp. 973 - U377
Activating B-RAF(V600E) (also known as BRAF) kinase mutations occur in similar to 7% of human malignancies and similar to 60% of melanomas(1). Early clinical... 
CELLS | MEK | PLX4032 | PATHWAY | MULTIDISCIPLINARY SCIENCES | KINASE | SENSITIVITY | BRAF | MUTATIONS | CRAF | CANCER
Journal Article
Journal Article
Cancer Discovery, ISSN 2159-8274, 09/2015, Volume 5, Issue 9, pp. 960 - 971
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 03/2013, Volume 19, Issue 5, pp. 1225 - 1231
Journal Article